Infliximab治疗强直性脊柱炎发生皮肤不良反应七例临床分析  

The clincial analysis of 7 ankylosing spondylitis patients with adverse cutaneous reactions to infliximab

作　　者：张莉芸[1] 黄烽[1] 张江林[1] 赵华[2] 刘湘源[1] 朱剑[1] 赵伟[1] 邓小虎[1] 邹艳红[3] 

机构地区：[1]解放军总医院风湿科 [2]解放军总医院皮肤科 [3]黑龙江省大庆市第一医院

出　　处：《中华风湿病学杂志》2005年第3期166-168,共3页Chinese Journal of Rheumatology

摘　　要：目的探讨抗肿瘤坏死因子单克隆抗体infliximab的皮肤不良反应。方法在一项2个中心的开放性研究中,对infliximab治疗活动性强直性脊柱炎的安全性进行评估,所有患者在0、2、6周静脉输注infliximab5mg/kg,并随诊观察至10周,对出现皮肤不良反应的患者进行治疗,直至病情缓解。结果63例患者纳入研究,7例(11%)出现皮肤病变,包括毛囊炎、皮下脂肪瘤感染、足癣各1例,荨麻疹、迟发过敏性反应性皮炎伴严重脱发各2例,其中1例发生荨麻疹时伴有呼吸困难,未完成第3次液体的输注,另外2例迟发过敏性反应性皮炎病例为严重不良事件。结论Infliximab的皮肤不良反应常见,临床表现多样,多为轻度至中度,少数为重度。随着该药在临床的推广应用,应对其皮肤不良反应引起足够重视。Objective To investigate the adverse cutaneous reactions to infliximab. Methods This is an open-labeled, two-centre study to assess efficacy and safety of infliximab in patients with active ankylosing spondylitis. All patients were treated with intravenous infliximab (5 mg/kg) at 0, 2, 6 weeks, and followed up to 10 weeks. Patients who developed cutaneous adverse effects would be treated until the disease recovered. Results Sixty-three patients were enrolled in this study. Seven (11%) patients had adverse cutaneous reactions. The following diagnoses were made: folliculitis, infection of subcutaneous fat tissue, fungal dermatitis in feet, urticaria (2 patients), delayed hypersensitive reaction of skin with alopecia (2 patients). Conclusion Adverse cutaneous effects of infliximab are common and various. Most of them are mild, but some are serious. Adverse cutaneous effects of infliximab should be alerted.

关 键 词：INFLIXIMAB 治疗 强直性脊柱炎 皮肤不良反应 临床分析 

分 类 号：R593.23[医药卫生—内科学]